← All trials
NCT01541852
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2012
- Primary completion
- Feb 1, 2014
- Completion date
- Feb 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CambridgeLead sponsor
- GlaxoSmithKlineCollaborator
- University of CambridgeCollaborator
- Technology Strategy Board, United KingdomCollaborator
- University of CambridgeOverall official - principal investigator
- University of CambridgeReponsible party - principal investigator
- University of LondonOverall official - principal investigator
- University of LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.